Werewolf Therapeutics, an MPM investment, emerged from stealth mode in 2019 with $56M in funding led by serial entrepreneur Dan Hicklin. The company later went public in 2021 tapping the capital markets to finance its pipeline of novel oncology assets.
In August 2020, Occam recruited Ellen Lubman to be CBO. In Lubman, Werewolf captures a richly experienced business development executive with an elevated strategic mind, virtues that will serve the company well as it seeks to deliver on the potential of its robust immunomodulatory platform.
